| A proteomic atlas of senescence-associated secretomes for aging biomarker development N Basisty, A Kale, OH Jeon, C Kuehnemann, T Payne, C Rao, A Holtz, ... PLoS biology 18 (1), e3000599, 2020 | 822 | 2020 |
| Sirtuin 5 regulates proximal tubule fatty acid oxidation to protect against AKI T Chiba, KD Peasley, KR Cargill, KV Maringer, SS Bharathi, E Mukherjee, ... Journal of the American Society of Nephrology 30 (12), 2384-2398, 2019 | 94 | 2019 |
| Accumulation of “Old Proteins” and the critical need for MS‐based protein turnover measurements in aging and longevity N Basisty, A Holtz, B Schilling Proteomics 20 (5-6), 1800403, 2020 | 25 | 2020 |
| Quantification and Identification of Post-Translational Modifications Using Modern Proteomics ApproachesProteomicsapproaches A Holtz, N Basisty, B Schilling Quantitative Methods in Proteomics, 225-235, 2021 | 13 | 2021 |
| Simultaneous affinity enrichment of two post-translational modifications for quantification and site localization X Xie, S Shah, A Holtz, J Rose, N Basisty, B Schilling JoVE (Journal of Visualized Experiments), e60780, 2020 | 10 | 2020 |
| Proteomic analysis of Huntington’s disease medium spiny neurons identifies alterations in lipid droplets KT Tshilenge, CG Aguirre, J Bons, AA Gerencser, N Basisty, S Song, ... Molecular & Cellular Proteomics 22 (5), 2023 | 8 | 2023 |
| Dual blockade of EP2 and EP4 signaling is required for optimal immune activation and antitumor activity against prostaglandin-expressing tumors BJ Francica, A Holtz, J Lopez, D Freund, A Chen, D Wang, D Powell, ... Cancer Research Communications 3 (8), 1486-1500, 2023 | 4 | 2023 |
| Systemic small molecule TREX1 inhibitors to selectively activate STING in the TME of metastatic disease B Francica, D Burdette, R Clark, J Cope, D Freund, A Holtz, P Prasit, ... Cancer Res 82 (12 Suppl), 2075, 2022 | 4 | 2022 |
| 1331 Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway J Lopez, A Holtz, D Freund, D Burdette, D Wang, R Duboise, S Whiting, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2* | 2022 |
| Growth hormone receptor (GHR) expression confers resistance to ruxolitinib in endocrine-resistant breast cancer cells AN Holtz, D Yee, H Beckwith Cancer Research 78 (13_Supplement), 5839-5839, 2018 | 2 | 2018 |
| Generation of novel potent human TREX1 inhibitors facilitated by crystallography V Chen, B Francica, D Hsieh, D Freund, A Holtz, S Samanta, J Cope, ... Cancer Res 83, 1636, 2023 | 1 | 2023 |
| Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway B Francica, J Lopez, A Holtz, D Freund, D Wang, A Enstrom, R Dubois, ... Cancer Research 82 (12_Supplement), 1333-1333, 2022 | 1 | 2022 |
| Neuronal Glycogen Breakdown Mitigates Tauopathy via Pentose Phosphate Pathway-Mediated Oxidative Stress Reduction S Bar, KA Wilson, TAU Hilsabeck, S Alderfer, EB Dammer, JB Burton, ... Research Square, 2023 | | 2023 |
| Neuronal Glycogen Breakdown Mitigates Tauopathy via Pentose Phosphate Pathway-Mediated Oxidative Stress Reduction P Kapahi, S Bar, K Wilson, T Hilsabeck, S Alderfer, E Dammer, J Burton, ... | | 2023 |
| Crystallography-guided characterization of novel cytosolic DNase 3’repair exonuclease 1 (TREX1) inhibitors V Chen, D Hsieh, D Freund, A Holtz, JG Lopez, A Mullenix, J Cope, ... Communications, 10.1038, 2022 | | 2022 |
| Abstract P5-03-05: Model of acquired resistance to the tyrphostin NT157 in hormone receptor-positive breast cancer RC Ekyalongo, R Abdelwahab, A Holtz, A Sabet, D Yee Cancer Research 79 (4_Supplement), P5-03-05-P5-03-05, 2019 | | 2019 |
